Management of Persistent Epistaxis Using Floseal Hemostatic Matrix

Status Completed

Clinical Trial Summary

Nosebleeds that persist even after adequate traditional nasal packing may require aggressive treatment strategies to stop bleeding. Currently these strategies include a surgical approach to cut off blood supply to the vessel that is bleeding. FloSeal Hemostatic matrix is a gel like medical therapy that is inserted into the nose and is engineered to stop bleeding in severe cases, possibly avoiding the need for surgery. In this study the investigators will randomize patients to either receive FloSeal Hemostatix matrix or traditional nasal packing as a treatment for severe nosebleeds. The main outcome will be whether the investigators are able to stop bleeding with FloSeal or traditional packing alone and whether additional measures are necessary to stop the bleeding. The investigators will also perform a patient comfort survey and cost analysis. Even if FloSeal has equal effectiveness in treating nosebleeds as traditional packing, if it is much more comfortable for patients then it may be the favourable treatment.

Clinical Trial Description

Background: Epistaxis is the most common emergent consultation to otolaryngology-head & neck surgery (OHNS) and with 60% of the population having experienced an episode and 1.6 in 10,000 requiring hospitalization in their lifetime. In preliminary studies Floseal® (Baxter, USA) Hemostatic Matrix has shown efficacy in up to 80% of persistent anterior epistaxis. We sought to evaluate the clinical efficacy¬ and cost-effectiveness of Floseal® (Baxter, USA) compared to traditional nasal packing for persistent epistaxis. Methods: A prospective, randomized controlled trial was conducted on all adult patients consulted to the OHNS service at the tertiary referral centers of the University of Alberta Hospital and Royal Alexandra Hospital for persistent epistaxis. Patients were randomized to the Floseal® (Baxter, USA) or traditional packing study arms. Our main clinical outcome measures were: 1) Hemostasis directly following treatment and at 48 hours post-treatment, and 2) self-reported patient comfort at 48 hours post-treatment. Further, trial data was used for a formal cost-effectiveness analysis to determine incremental cost-effectiveness ratio (ICER). Univariate sensitivity analysis and uncertainty analysis were performed. ;

Study Design

Related Conditions & MeSH terms

Epistaxis

Clinical Trial Details

NCT number	NCT02488135
Study type	Interventional
Source	University of Alberta
Contact
Status	Completed
Phase	N/A
Start date	July 1, 2015
Completion date	March 1, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05334017` - Xylometazoline and Cocaine for Nasal Vasoconstriction	Phase 4
Not yet recruiting	`NCT04519463` - The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing	Early Phase 1
Recruiting	`NCT01886768` - Double Versus Single Pledget Nasal Anesthesia for Transnasal Endoscopy	N/A
Recruiting	`NCT00390663` - A Prospective Randomised Controlled Trial of Management of Recurrent Nosebleeds in Children	Phase 4
Suspended	`NCT04054687` - Intranasal TXA for Anterior Epistaxis in the Emergency Department	Phase 2
Completed	`NCT02285634` - The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.	N/A
Completed	`NCT01485224` - Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia	Phase 2
Completed	`NCT00793117` - The Effect of Packing in Post Operative Management of FESS	Phase 4
Recruiting	`NCT06259292` - Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Recruiting	`NCT03850964` - Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)	Phase 2/Phase 3
Recruiting	`NCT05281952` - Medico-economic Evaluation of Management Strategies for Severe Epistaxis	N/A
Completed	`NCT03360045` - Comparing Effectiveness of Merocel and Packing With Tranexamic Acid in the Management of Anterior Epistaxis	Phase 4
Completed	`NCT04279288` - The Roles of Hilotherapy in the Management of Epistaxis and Nasal Fractures	N/A
Completed	`NCT03912051` - Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting	N/A
Not yet recruiting	`NCT02677467` - Correlation Between Epistaxis and Cardiovascular Disease	N/A
Completed	`NCT01314274` - Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)	Phase 2
Terminated	`NCT01051427` - Control of Epistaxis With Surgiflo	N/A
Completed	`NCT00863356` - Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis	N/A
Recruiting	`NCT05269849` - Sirolimus for Nosebleeds in HHT	Phase 2
Not yet recruiting	`NCT05343650` - NOVAPAK Nasal Packing in Shellfish Allergic Patients	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.